tiprankstipranks
Advertisement
Advertisement
Analyst Reiterates Buy on Biomea Fusion, Maintains $4 Price Target Amid Advancing Metabolic Pipeline
PremiumRatingsAnalyst Reiterates Buy on Biomea Fusion, Maintains $4 Price Target Amid Advancing Metabolic Pipeline
3M ago
Biomea Fusion reports Q1 EPS (17c), consensus (19c)
Premium
The Fly
Biomea Fusion reports Q1 EPS (17c), consensus (19c)
3M ago
Biomea Fusion options imply 18.9% move in share price post-earnings
Premium
The Fly
Biomea Fusion options imply 18.9% move in share price post-earnings
3M ago
Biomea Fusion announces positive 52-week results from phase 2 COVALENT-112 trial
PremiumThe FlyBiomea Fusion announces positive 52-week results from phase 2 COVALENT-112 trial
3M ago
Biomea Fusion Advances Phase 2 Add-On Therapy Trial in Ozempic-Treated Diabetes
Premium
Company Announcements
Biomea Fusion Advances Phase 2 Add-On Therapy Trial in Ozempic-Treated Diabetes
4M ago
Biomea Fusion Advances Mid‑Stage Diabetes Trial, Adding a New Angle to the BMEA Investment Story
Premium
Company Announcements
Biomea Fusion Advances Mid‑Stage Diabetes Trial, Adding a New Angle to the BMEA Investment Story
4M ago
Biomea Fusion Updates Corporate Presentation on Metabolic Pipeline
PremiumCompany AnnouncementsBiomea Fusion Updates Corporate Presentation on Metabolic Pipeline
5M ago
Biomea Fusion Highlights Diabetes Pipeline at JPM Conference
Premium
Company Announcements
Biomea Fusion Highlights Diabetes Pipeline at JPM Conference
7M ago
Biomea Fusion initiated with a Buy at Rodman & Renshaw
Premium
The Fly
Biomea Fusion initiated with a Buy at Rodman & Renshaw
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100